Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

A Study to investigate the Safety and Efficacy of Daclizumab to treat the ocular complications related to the Behcet’s disease

Go back to Resources

A Study to investigate the Safety and Efficacy of Daclizumab to treat the ocular complications related to the Behcet’s disease

Authors:

Location:

Go back to Resources

A severity scale for Age-Related Macular Degeneration (AMD)

Go back to Resources

A severity scale for Age-Related Macular Degeneration (AMD)

Authors:

Location:

Go back to Resources

A prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation

Go back to Resources

A prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

A National Cancer Institute Pilot Study to Enhance Enrollment in Clinical Trials: The Expanded Participation Project (EPP)

Go back to Resources

A National Cancer Institute Pilot Study to Enhance Enrollment in Clinical Trials: The Expanded Participation Project (EPP)

Authors:

Location:

Go back to Resources

A multicenter randomized double-masked clinical trial of a new formulation of topical Cysteamine for the treatment of Corneal Cystine Crystals in cystinosis

Go back to Resources

A multicenter randomized double-masked clinical trial of a new formulation of topical Cysteamine for the treatment of Corneal Cystine Crystals in cystinosis

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review

Go back to Resources

Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Prograf as secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure (CRAF) results in improved renal function, decreased CV risk, and no increased risk for diabetes

Go back to Resources

Prograf as secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure (CRAF) results in improved renal function, decreased CV risk, and no increased risk for diabetes

Authors:

Location:

Go back to Resources

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

Go back to Resources

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Palivizumab prophylaxis of RSV disease: demographic and risk factors results from the 2002-2003 Outcomes Registry

Go back to Resources

Palivizumab prophylaxis of RSV disease: demographic and risk factors results from the 2002-2003 Outcomes Registry

Authors:

Location:

Go back to Resources

Palivizumab prophylaxis of respiratory syncytial virus (RSV) - results from the 2000-2001 Synagis Outcomes Registry

Go back to Resources

Palivizumab prophylaxis of respiratory syncytial virus (RSV) - results from the 2000-2001 Synagis Outcomes Registry

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 141
  • Page 142
  • Page 143
  • Page 144
  • Current page 145
  • Page 146
  • Page 147
  • Page 148
  • Page 149
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification